Semaglutide vs Mazdutide
Mazdutide builds on the GLP-1 foundation that semaglutide established by adding glucagon-receptor activity. Comparing them isolates exactly what the glucagon arm contributes.
| Semaglutide | Mazdutide | |
|---|---|---|
| Compound class | GLP-1 receptor agonist | Dual GLP-1/glucagon receptor agonist |
| Primary target | GLP-1 receptor | GLP-1 + glucagon receptors |
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Administration | Weekly subcutaneous | Weekly subcutaneous |
| Research focus | Appetite signaling & glycemic control | Weight & hepatic metabolic endpoints |
Key differences
- Mechanism: semaglutide is GLP-1 only; mazdutide is GLP-1 plus glucagon.
- Glucagon effect: mazdutide's second receptor is studied for energy expenditure and hepatic endpoints absent in semaglutide.
- Maturity: semaglutide has the larger, more established dataset; mazdutide is the newer dual agonist.
- Both are weekly subcutaneous compounds that titrate upward.
Which is right for your research?
Semaglutide is the GLP-1 baseline; mazdutide is the dual-agonist step that introduces glucagon signaling.
Frequently asked questions
How does mazdutide differ from semaglutide?
Semaglutide targets GLP-1 alone, while mazdutide adds glucagon-receptor agonism, making it a dual agonist.
Which has more research behind it?
Semaglutide has the deeper dataset; mazdutide is newer and still building its research base.
Are they administered the same way?
Yes — both are weekly subcutaneous research compounds titrated over time.
For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.